Targeting coagulation to the tumor microvasculature: Perspectives and therapeutic implications from preclinical studies

Journal of the National Cancer Institute

Volumn 97, Issue 10, 2005, Pages 705-707

  Narazaki, Masashi ^a   Tosato, Giovanna ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE P; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CADHERIN; CD51 ANTIGEN; CYTOTOXIC AGENT; HYBRID PROTEIN; INTERLEUKIN 12; LIPOCORTIN 1; MATRIX METALLOPROTEINASE; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1 MONOCLONAL ANTIBODY THROMBOPLASTIN PROTEIN CONJUGATE; VASCULAR TARGETING AGENT; VASCULOTROPIN; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ARTIFICIAL EMBOLISM; BINDING AFFINITY; BIOINFORMATICS; CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; IMMUNOSTIMULATION; MICROVASCULATURE; PERICYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEOMICS; RADIOIMMUNOTHERAPY; RISK REDUCTION; SOLID TUMOR; SURVIVAL RATE; TISSUE SPECIFICITY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; ANIMAL; DRUG EFFECT; METABOLISM; MICROCIRCULATION; NECROSIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NOTE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROCIRCULATION; NECROSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 20544455656     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji152     Document Type: Editorial

References (32)

1. Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73-85.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
5. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
6. Isner JM, Kalka C, Kawamoto A, Asahara T. Bone marrow as a source of endothelial cells for natural and iatrogenic vascular repair. Ann N Y Acad Sci 2001;953:75-84.
7. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
8. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496-507.
9. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
12. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-8.
13. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
14. Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta 2004;1654:39-49.
15. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8-24.
16. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
17. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
18. Dienst A, Grunow A, Unruh M, Rabausch B, Nör JE, Fries JW, et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005;97:733-47.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
20. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6.
21. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
22. Marchio S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004;5:151-62.
23. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289: 1197-202.
24. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429:629-35.
25. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002;99:7866-71.
26. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9.
27. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991;266:16256.
28. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50.
29. Auerbach R. Vascular endothelial cell differentiation: organ-specificity and selective affinities as the basis for developing anti-cancer strategies. Int J Radiat Biol 1991;60:1-10.
30. Nikolova G, Lammert E. Interdependent development of blood vessels and organs. Cell Tissue Res 2003;314:33-42.
31. Prandini MH, Dreher I, Bouillot S, Benkerri S, Moll T, Huber P. The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene 2005;24:2992-3001.
32. Pai JT, Ruoslahti E. Identification of endothelial genes up-regulated in vivo. Gene 2005;347:21-33.